Overview Request Sample Pages Request Customization Download PDF
You are viewing: Europe Veterinary Biologics Market analysis
Part of: Veterinary Biologics Market (Global)

The Europe Veterinary Biologics Market was valued at $734.46 Million in 2025 and projected to reach to $939.18 Million by 2030, representing a compound annual growth rate of 5.0%. Europe's veterinary biologics market is poised for sustained growth driven by increasing pet ownership, rising awareness of preventive animal healthcare, and growing demand for advanced biological treatments.

Europe Veterinary Biologics Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Europe Veterinary Biologics Market Trends and Insights

  • This steady expansion reflects Europe's strong regulatory framework, advanced veterinary healthcare infrastructure, and increasing investment in animal health innovation.
  • Europe maintains a mature market position with established distribution networks and high adoption rates of biologics across companion and livestock segments. The growth trajectory in Europe is driven by rising awareness of preventive animal healthcare, stringent biosecurity regulations, and the region's commitment to sustainable farming practices.
  • Europe's veterinary biologics sector benefits from robust research and development capabilities and collaboration between academic institutions and pharmaceutical manufacturers.
  • Between 2025 and 2030, Europe is expected to consolidate its leadership in vaccine development and immunotherapy solutions for animals..

Key Market Statistics

  • CAGR (2025-2030) 5.0% CAGR
  • Market Size, 2025 ~USD 734.46 Million
  • Forecast, 2030 ~USD 939.18 Million
  • Geography Europe

Europe Veterinary Biologics Market Overview

Market Valuation & Growth :

Europe's veterinary biologics market is valued at $734.46 million in 2025 and is projected to reach $939.18 million by 2030, representing a steady 5.0% CAGR, demonstrating consistent market expansion across the region.

Regulatory Excellence :

Europe benefits from a robust regulatory framework with stringent quality standards and established approval pathways through the European Medicines Agency (EMA), ensuring high-quality veterinary biologics and fostering market confidence.

Advanced Healthcare Infrastructure :

The region's mature veterinary healthcare infrastructure, coupled with significant investment in animal health innovation, positions Europe as a leader in developing and adopting advanced biological therapeutics for companion and livestock animals.

Key Market Contributors :

Germany leads European market with $125.77 million, followed by the UK ($99 million) and France ($95.48 million), collectively representing the strongest demand centers for veterinary biologics in the region.

Europe Veterinary Biologics Market Dynamics

  • The region's commitment to animal welfare standards and regulatory compliance continues to attract investment in innovative biologics development.
  • Emerging markets within Eastern Europe present additional growth opportunities as veterinary healthcare infrastructure expands. The forecast period through 2030 will likely see accelerated adoption of immunotherapies, vaccines, and regenerative medicine products across Europe.
  • Consolidation among veterinary pharmaceutical companies and strategic partnerships with research institutions will further strengthen the market.
  • Sustainability initiatives and the shift toward personalized veterinary medicine are expected to shape product development strategies and create new revenue streams for market participants..

Related Ecosystem

Animal Health

Top Technologies
  • Polymerase Chain Reaction (PCR) Tests
  • Porcine
  • Immunodiagnostics
  • Lateral Flow Assays
  • Microarrays
Top Companies
  • Zoetis Inc.
  • Patterson Companies, Inc.
  • Virbac
  • Elanco Animal Health Incorporated
  • BOEHRINGER INGELHEIM GMBH

    Key Takeaways

    • Europe's veterinary biologics market reaches $734.46 million in 2025 with projected growth to $939.18 million by 2030.
    • Europe maintains a 5.0% CAGR, reflecting steady demand for advanced animal health solutions and preventive care.
    • Europe's mature regulatory environment and strong R&D infrastructure support innovation in vaccines and immunotherapies.
    • Europe's commitment to biosecurity and sustainable farming practices drives adoption of veterinary biologics across livestock and companion animals.

    Veterinary Biologics Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment CANINE (Type)
    Forecast Period 2025–2030
    Growth Rate CAGR of 5.2% from 2025 to 2030
    Largest Segment INJECTABLE ROUTE OF ADMINISTRATION (Route Of Administration)
    Market Size Base Year (Billions) ~USD 2.72 (2025)
    Revenue Forecast (Billions) ~USD 3.51 (2030)
    Segments Covered Product Type, Animal Type, Type, Route Of Administration, Application, End User

    Europe Veterinary Biologics Market Report Segmentation

    6 segment dimensions are covered across the global market.

    By Product Type

    • Diagnostic Kits
    • Immunodmodulators & Immunostimulants
    • Immunoglobulins & Antitoxins
    • Immunomodulators & Immunostimulants
    • Immuoglobulins & Antitoxins
    • Monoclonal Anitbodies
    • Monoclonal Antibodies

    By Animal Type

    • Companion Animal
    • Companion Animals
    • Livestock Animal
    • Livestock Animals

    By Type

    • Bovine
    • Canine
    • Equine
    • Feline
    • Intramuscular Route Of Administration
    • Intravenous Route Of Administration
    • Other Injectable Route Of Administration
    • Porcine
    • Poultry
    • Small Ruminant
    • Subcutaneous Route Of Administration

    By Route Of Administration

    • Injectable Route Of Administration
    • Oral Route Of Administration
    • Other Routes Of Administration

    By Application

    • Dermatology
    • Diagnostic Testing
    • Diagnostic Tetsing
    • Infectious Disease Prevention
    • Oncology
    • Other Applications
    • Pain Management

    By End User

    • Other End Users
    • Veterinary Diagnostic Labs
    • Veterinary Hospitals & Clinics

    EUROPE: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    OTHER END USERS28.829.430.130.831.732.733.935.13.1
    VETERINARY DIAGNOSTIC LABS172177182.5188.7195.6203.3211.9221.23.9
    VETERINARY HOSPITALS & CLINICS477.2498.5521.9548.1576.8608.7644.4682.95.5
    TOTAL678704.8734.5767.7804.1844.6890.2939.25

    REST OF EUROPE: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    OTHER END USERS3.453.53.553.623.73.793.8942.4
    VETERINARY DIAGNOSTIC LABS20.4420.8821.3721.9422.5723.2824.124.963.2
    VETERINARY HOSPITALS & CLINICS61.1163.3665.8368.6171.6575.0478.8482.914.7
    TOTAL85.0187.7390.7694.1797.92102.1106.82111.874.3

    Target Audience

    • Veterinary Pharmaceutical Companies : Manufacturers and distributors of veterinary biologics need Europe-specific market data to identify growth opportunities, assess competitive positioning, and develop region-tailored product strategies aligned with regulatory requirements.
    • Investment & Private Equity Firms : Investors evaluating opportunities in the veterinary healthcare sector require detailed European market analysis, growth projections, and country-level performance metrics to guide acquisition and portfolio decisions.
    • Market Entry & Business Development Teams : Companies planning European expansion need comprehensive market intelligence including regulatory pathways, competitive dynamics, and country-specific market sizes to develop effective go-to-market strategies.
    • Veterinary Clinics & Hospital Networks : Large veterinary practice groups and hospital chains use market data to understand product availability, emerging treatment options, and procurement trends to enhance service offerings and clinical outcomes.
    • Research & Academic Institutions : Universities and research organizations studying veterinary medicine and animal health innovation require market data to identify research gaps, commercialization opportunities, and funding priorities aligned with market demand.

    Key Companies in the Europe Veterinary Biologics Market

    CompanyHQOwnershipStrongest segments
    IDEXXUnited StatesPublic CompanyCompanion Animal Group (in-clinic diagnostics, reference labs, services, software),Water Quality Products,Livestock, Poultry and Dairy (including related diagnostics),
    ELANCOUnited StatesPublic CompanyCompanion animal parasiticides (Seresto, K-9 Advantage, Advantix, Advocate, Credelio Family, Interceptor Plus, Drontal),Companion animal vaccines and therapeutics (Galliprant, Atopica, Milbemax, Onsior, Tru Family),Farm animal feed additives and productivity enhancers (Rumensin, Experior, Hemicell, Surmax, Pulmotil),
    MERCK & CO., INC.United StatesPublic CompanyOncology (Keytruda, Keytruda Qlex, Welireg, ADC collaborations),Vaccines (Gardasil, pediatric and adult vaccines including Vaxneuvance, Capvaxive),Cardiovascular, pulmonary hypertension and specialty (Winrevair, Adempas/Verquvo, Ohtuvayre, others),
    THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
    NEOGEN CORPORATIONUnited StatesPublic CompanyFood Safety diagnostics, media, and sanitation,Animal Safety instruments, care products, and biosecurity,Genomics services for livestock and companion animals,
    BIO-RAD LABORATORIES, INC.United StatesPublic CompanyClinical Diagnostics,Life Science Research Instruments and Systems,Life Science Reagents and Consumables,
    IMMUCELL CORPORATIONUnited StatesPublic CompanyFirst Defense (core scours prevention),Tri-Shield First Defense,Dual-Force First Defense and related formulations,

    IDEXX

    IDEXX is a public company founded in 1983 and headquartered in the United States, employing 11,000 people.

    ELANCO

    Elanco is a public company founded in 1954 in the United States with 9,650 employees.

    MERCK & CO., INC.

    Merck & Co., Inc. is a public pharmaceutical company founded in 1891 and based in the United States, with 74,000 employees.

    THERMO FISHER SCIENTIFIC INC.

    Thermo Fisher Scientific Inc. is a public company founded in 1956 in the United States and employs 125,000 people.

    NEOGEN CORPORATION

    Neogen Corporation is a public company founded in 1981 in the United States with 2,974 employees.

    BIO-RAD LABORATORIES, INC.

    Bio-Rad Laboratories, Inc. is a public company founded in 1952 in the United States and employs 7,450 people.

    IMMUCELL CORPORATION

    ImmuCell Corporation is a public company founded in 1982 in the United States with 73 employees.

    Europe vs. other regions

    HowEurope compares to the other 3 regional blocs covered in this market.

    North America
    ~USD 1754.2 Million · 5.6% wtd CAGR ·
    Asia Pacific
    ~USD 555.52 Million · 4.9% wtd CAGR ·
    Latin America
    ~USD 168.46 Million · 4.1% wtd CAGR ·
    Middle East & Africa
    ~USD 91.66 Million · 2.8% wtd CAGR ·

    Countries within Europe - compare and drill down

    Country2025 size (native)
    GermanyUSD 125.77 Million
    UKUSD 99 Million
    FranceUSD 95.48 Million
    ItalyUSD 59.59 Million
    SpainUSD 56.49 Million
    NetherlandsUSD 44.01 Million
    Rest Of EuropeUSD 68.36 Million

    Country market size visualization

    Germany
    USD 125.77 Million
    UK
    USD 99 Million
    France
    USD 95.48 Million
    Italy
    USD 59.59 Million
    Spain
    USD 56.49 Million
    Netherlands
    USD 44.01 Million
    Rest Of Europe
    USD 68.36 Million

    Reasons to Buy this Report

    • Regional Market Segmentation : Gain detailed insights into Europe's veterinary biologics market with country-level breakdowns including Germany, UK, France, Italy, Spain, and Netherlands, enabling precise market targeting and localized strategy development.
    • Regulatory & Compliance Intelligence : Understand Europe's stringent regulatory landscape and EMA approval processes, critical for companies seeking market entry or expansion in this highly regulated region with established quality standards.
    • Competitive Landscape Analysis : Identify key market players, competitive positioning, and market share distribution across Europe's mature veterinary biologics sector to inform strategic partnerships and investment decisions.
    • Growth Opportunity Identification : Discover emerging segments within companion animal and livestock biologics, identify underserved markets in Eastern Europe, and capitalize on the region's shift toward preventive and personalized veterinary medicine.
    • Investment & Expansion Planning : Access comprehensive market forecasts through 2030 with 5% CAGR projections to support business planning, capital allocation, and market entry strategies for veterinary biologics companies targeting European expansion.

    Frequently asked questions

    What is the current size of Europe's veterinary biologics market?

    Europe's veterinary biologics market is valued at $734.46 million in 2025.

    What is the projected market size for Europe's veterinary biologics by 2030?

    Europe's veterinary biologics market is projected to reach $939.18 million by 2030.

    What is the growth rate for Europe's veterinary biologics market?

    Europe's veterinary biologics market is expected to grow at a compound annual growth rate of 5.0% from 2025 to 2030.

    What factors are driving growth in Europe's veterinary biologics market?

    Growth in Europe is driven by rising awareness of preventive animal healthcare, stringent biosecurity regulations, sustainable farming practices, and strong R&D capabilities.

    How does Europe's veterinary biologics market compare to other regions?

    Europe maintains a mature market position with established distribution networks, advanced regulatory frameworks, and high adoption rates of biologics across companion and livestock segments.

    RESEARCH METHODOLOGY

    This study extensively used both primary and secondary sources. The research process examined various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, market dynamics, and strategies of major players.

    Secondary Research

    This research involved the use of comprehensive secondary sources, including directories; databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was employed to gather information for an extensive, technical, market-focused, and commercial analysis of the veterinary biologics market. It also helped obtain crucial details about key players, market classification, and segmentation based on industry trends at the most detailed levels, as well as significant developments related to market and technology perspectives. Additionally, a database of major industry leaders was created using secondary research.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to gather qualitative and quantitative information for this report. Primary sources from the supply side include project managers, sales managers, marketing managers, business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the veterinary biologics market. Primary sources from the demand side consist of professionals from veterinary hospitals and clinics, diagnostic labs, academic and research institutes, and pet owners.

    A breakdown of the primary respondents is provided below:

    Veterinary Biologics Market

    Note 1: C-level primaries include CEOs, CFOs, COOs, and VPs.

    Note 2: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

    Note 3: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = < USD 1.00 billion.

    Source: MarketsandMarkets Analysis

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The total size of the veterinary biologics market was determined through data triangulation from three different approaches, as outlined below. After each approach, a weighted average was calculated based on the level of assumptions used in each method.

    Veterinary Biologics Market

    Data Triangulation

    After defining the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown methods were used where applicable to complete the overall market analysis and determine accurate statistics for all segments and subsegments. The following figure illustrates the market validation, source structure, and data triangulation approach used in the market analysis process.

    Market Definition

    The veterinary biologics market includes all USDA-regulated biologic products, such as monoclonal antibodies, immunoglobulins, immunomodulators, and diagnostic kits, which are used for the prevention, diagnosis, or treatment of animal diseases. These products serve companion animals, livestock, and poultry across veterinary clinics, hospitals, diagnostic labs, and farm or herd settings, enabling veterinarians and animal health professionals to provide targeted immune-based interventions and rapid diagnostic testing. This allows infected animals to be identified quickly for faster treatment, containment, or herd management decisions.

    Stakeholders

    • Veterinary Biologics Manufacturers
    • Animal Healthcare Product Manufacturers
    • Veterinary Biologics Distributors and Wholesalers
    • Animal Welfare Associations
    • Veterinary Clinics and Care Centers
    • Research And Consulting Firms
    • Veterinary Research and Development Organizations
    • Contract Manufacturing Organizations
    • Venture Capitalists

    Report Objectives

    • To define, describe, and forecast the veterinary biologics market by product type, animal type, route of administration, application, end user, and region.
    • To provide detailed information about the key factors, such as drivers, restraints, opportunities, challenges, and industry trends, influencing the market growth
    • To strategically analyze the regulatory scenario, value chain analysis, supply chain analysis, Porter’s Five Forces analysis, ecosystem analysis, trade analysis, pricing analysis, patent analysis, impact of AI on veterinary biologics market, case study analysis, adjacent market analysis, unmet needs/end user expectations in veterinary biologics market, and trends/disruption impacting customer business in the market
    • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
    • To strategically analyze the market in five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
    • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
    • To strategically profile the key players in this market and comprehensively analyze their market shares and core competencies
    • To track and analyze competitive developments such as product launches and approvals, partnerships, and expansions in the market

     

    Get the Full Veterinary Biologics Market Report

    Full forecast, segment splits, and company analysis for all Veterinary Biologics Market.

    Download Sample Pages Buy Report

    METHODOLOGY

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    Cite this Research
    DMCA.com Protection Status